Cargando…
The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study
AIMS: Patients with heart failure (HF) and iron deficiency experience poor health-related quality of life (HRQoL). We evaluated the impact of intravenous (IV) ferric carboxymaltose (FCM) vs. placebo on HRQoL for the AFFIRM-AHF population. METHODS AND RESULTS: The baseline 12-item Kansas City Cardiom...
Autores principales: | Jankowska, Ewa A, Kirwan, Bridget-Anne, Kosiborod, Mikhail, Butler, Javed, Anker, Stefan D, McDonagh, Theresa, Dorobantu, Maria, Drozdz, Jarosław, Filippatos, Gerasimos, Keren, Andre, Khintibidze, Irakli, Kragten, Hans, Martinez, Felipe A, Metra, Marco, Milicic, Davor, Nicolau, José C, Ohlsson, Marcus, Parkhomenko, Alexander, Pascual-Figal, Domingo A, Ruschitzka, Frank, Sim, David, Skouri, Hadi, van der Meer, Peter, Lewis, Basil S, Comin-Colet, Josep, von Haehling, Stephan, Cohen-Solal, Alain, Danchin, Nicolas, Doehner, Wolfram, Dargie, Henry J, Motro, Michael, Friede, Tim, Fabien, Vincent, Dorigotti, Fabio, Pocock, Stuart, Ponikowski, Piotr |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370759/ https://www.ncbi.nlm.nih.gov/pubmed/34080008 http://dx.doi.org/10.1093/eurheartj/ehab234 |
Ejemplares similares
-
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial
por: Metra, Marco, et al.
Publicado: (2022) -
Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis
por: Filippatos, Gerasimos, et al.
Publicado: (2023) -
Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial
por: Rosano, Giuseppe, et al.
Publicado: (2023) -
Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising AFFIRM‐AHF
por: McEwan, Phil, et al.
Publicado: (2021) -
Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency
por: Butler, Javed, et al.
Publicado: (2022)